Simulation Plus News Today

The global Biosimulation Market, which was valued at around US$ 2.6 billion in 2021, is anticipated to grow at a CAGR of 21.5% during the ensuing ten years, reaching US$ 20.9 billion by the end of 2032. The necessity to develop novel pharmaceuticals to treat rising ailments will be what will fuel the demand for bios...

New Jersey, United States,- Mr Accuracy Reports published new research on Global Computational Biology covering micro level of ana

The Wall Street firm said this stock is a category leader for model-informed drug development (MIDD), or simulations for biotech drug trials. 

Operator: Greetings, and welcome to the Simulations Plus Second Quarter Fiscal 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

/PRNewswire/ -- The "Global In-Silico Drug Discovery Market Report: By Product, Workflow, Technology, End-user - Industry Outlook and Demand Forecast to 2030"...

North America holds the largest market for biosimulation. The rising chronic disease among the population in the region and regulations implemented by the...

Disso India-2022 Online will have around 20 lectures from eminent professionals working in the pharmaceutical industry from around the world as well as academia

NEW YORK, May 5, 2022 /PRNewswire/ -- In 2021, the global in-silico drug discovery market was worth $2,331.8 million, and it is expected to reach $5,682.3 million by 2030, at a 10.4% CAGR from

Harding Loevner, an investment management firm, published its “Global Small Companies Equity Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here.

The first class Biosimulation market report works upon a number of industry and market parameters including latest trends, market segmentation, new market entry, industry forecasting, target market analysis, future directions, opportunity identification, strategic analysis, insights and innovation. An explicit marke...